Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone…
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiariesMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April…
WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind…
Enrollment to continue to the end of April to accommodate strong patient and site interestNAARDEN, the Netherlands and MIAMI, April…
The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression. The Otsuka-sponsored registry study is…
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidateKey takeaways:Participants in…
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced the release of its annual…
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…